Search Results - "Bergua Burgues, J. M."

Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens? by Suárez, E. U., Boluda, B., Lavilla, E., Tormo, M., Botella, C., Gil, C., Vives, S., Rodríguez, C., Serrano, J., Sayas, M. J., Martínez-Sánchez, P., Ramos, F., Bernal, T., Algarra, L., Bergua-Burgues, J. M., Pérez-Simón, J. A., Herrera, P., Barrios, M., Noriega-Concepción, V., Raposo-Puglia, J. A., Ayala, R., Barragán, E., Martínez-Cuadrón, D., Amigo, M. L., López-Lorenzo, J. L., Lázaro-García, A., Guimaraes, J. E., Colorado, M., García-Boyero, R., De Rueda-Ciller, B., Foncillas-García, M., Hong, A., Labrador, J., Alonso-Dominguez, J. M., Montesinos, P.

“…FLT3 -ITD and NPM1 mutations are key to defining the genetic risk profile of acute myeloid leukemia (AML). We aimed to assess the prognostic features of the…”
Get full text

P512: PRELIMINARY RESULTS OF VEN‐A‐QUI STUDY: A PHASE 1‐2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF AZACITIDINE OR LOW‐DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB IN NEWLY DIAGNOSED by Bergua‐Burgues, J. M., Rodríguez‐Veiga, R., Cano, I., Vall‐llovera, F., García‐Guiñon, A., Gómez‐Estruch, J., Colorado, M., Casas‐Avilés, I., Esteve‐Reyner, J., Verdugo, M. V., Ramos, F., Valero, M., Acuña‐Cruz, E., Boluda, B., Torres‐Miñana, L., Martínez‐López, J., Barragán, E., Ayala, R., Martínez‐Cuadrón, D., Montesinos, P.

Get full text

FIRST‐MIND: A PHASE IB, OPEN‐LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL by Belada, D, Kopeckova, K, Bergua Burgues, J. M, André, M, Pérez Persona, E, Pichler, P, Klöpfer, P, Brackertz, B, Lohrmann, E, Lahiry, A, Shah, N, Brugger, W, Burke, J. M, Nowakowski, G. S

Get full text

CHARACTERIZATION OF THE ONCOGENIC PHENOTYPE IN EXTRANODAL NATURAL KILLER/T‐CELL LYMPHOMA, NASAL TYPE THROUGH GENE EXPRESSION PROFILE. SPANISH LYMPHOMA GROUP GELTAMO by González-Barca, E, Gato, L, Esteve, A, Sanz‐Pamplona, R, Tomás, L, Rodriguez, M, Martín García‐Sancho, A, Córdoba, R, Monter, A, Bastos, M, Bergua Burgues, J. M, Sayas, M. J, Viguria Alegria, M. C, Sánchez Blanco, J. J, Roig, M, Luzardo Henriquez, H. D, Oña, R, Cabezudo, E, Infante, M. S, Queizan, J. A, Blanco Nuñez, O, Mozos, A, Climent, F, Piris, M. A

Get full text

PB2110: PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST‐MIND: A PHASE IB, OPEN‐LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE + R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA by Belada, D., Kopeckova, K., Bergua Burgues, J. M., Stevens, D., Nowakowski, G. S., Waldron‐Lynch, M., Hadar, N., Weirather, J., Lässig, C., Blair, D., Dreyling, M.

Get full text

P508: REAL LIFE EXPERIENCE USING FRONT‐LINE CPX‐351 FOR THERAPY‐RELATED AND AML‐MRC: RESULTS FROM THE SPANISH PETHEMA REGISTRY by Bernal, T., Rad, G., Laiglesia, A., Benavente, C., Garcia Noblejas, A., Garcia Belmonte, D., Riaza, R., Salamero, O., Foncillas, A., Roldán, A., Noriega Concepcion, V., Perez de Oteyza, J., Bergua Burgues, J. M., Lorente de Uña, S., Fuente Burguera, A., Garcia Perez, M. J., Lopez Lorenzo, J. L., Martinez, P., Alaez, C., Callejas, M., Martinez Chamorro, C., Rifon Roca, J., Amador Barciela, L., Lopez, M., Gomez Correcha, K., Lavilla Rubiera, E., Amigo, M. L., Vall‐Llovera, F., Garrido, A., Garcia Fortes, M., Miguel Llorente, D., Aules Leonardo, A., Cervero, C., Coll Jorda, R., Perez Encinas, M., Polo Zarzuela, M., Martinez Cuadron, D., Montesinos, P.

Get full text

LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R / R DLBCL by Carlo‐Stella, C., Kwiatek, M., Chung, M., Móciková, H., Bergua‐Burgues, J. M., Gao, S., Grosicki, S., Stathis, A., Toupin, D., Wang, Y., Wang, L., Hamadani, M.

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Carlo-Stella, C, Kwiatek, M, Chung, M, Móciková, H, Bergua-Burgues, J M, Gao, S, Grosicki, S, Stathis, A, Toupin, D, Wang, Y, Wang, L, Hamadani, M

Get full text

LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL by Carlo‐Stella, C., Kwiatek, M., Chung, M., Móciková, H., Bergua‐Burgues, J. M., Gao, S., Grosicki, S., Stathis, A., Toupin, D., Wang, Y., Wang, L., Hamadani, M.

Get full text

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma by Tilly, Hervé, Morschhauser, Franck, Sehn, Laurie H, Friedberg, Jonathan W, Trněný, Marek, Sharman, Jeff P, Herbaux, Charles, Burke, John M, Matasar, Matthew, Rai, Shinya, Izutsu, Koji, Mehta-Shah, Neha, Oberic, Lucie, Chauchet, Adrien, Jurczak, Wojciech, Song, Yuqin, Greil, Richard, Mykhalska, Larysa, Bergua-Burgués, Juan M, Cheung, Matthew C, Pinto, Antonio, Shin, Ho-Jin, Hapgood, Greg, Munhoz, Eduardo, Abrisqueta, Pau, Gau, Jyh-Pyng, Hirata, Jamie, Jiang, Yanwen, Yan, Mark, Lee, Calvin, Flowers, Christopher R, Salles, Gilles

“…The treatment outcome for diffuse large B-cell lymphoma has not been improved in nearly 20 years. However, the replacement of vincristine in R-CHOP with…”
Get full text

ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study by Flowers, Christopher, Tilly, Hervé, Morschhauser, Franck, Sehn, Laurie H., Friedberg, Jonathan W., Trněný, Marek, Sharman, Jeff P., Herbaux, Charles, Burke, John M., Matasar, Matthew, Rai, Shinya, Izutsu, Koji, Mehta-Shah, Neha, Oberic, Lucie, Chauchet, Adrien, Jurczak, Wojciech, Song, Yuqin, Greil, Richard, Mykhalska, Larysa, Bergua-Burgués, Juan Miguel, Cheung, Matthew C., Pinto, Antonio, Shin, Ho-Jin, Hapgood, Greg, Munhoz, Eduardo, Abrisqueta, Pau, Gau, Jyh-Pyng, Hirata, Jamie, Jiang, Yanwen, Yan, Mark, Lee, Calvin, Salles, Gilles

“…Context: R-CHOP is the standard of care for newly diagnosed DLBCL patients; however, 40% remain uncured. Polatuzumab vedotin (Pola), a CD79b-targeting…”
Get full text

Congenital dyserythropoietic anemia morphologically type I with a positive HEMPAS phenomenon by Bergua Burgués, J M, Navarro, D, González, J, Doblaré, E

“…A patient with clinical and morphological anaemia of type I is described. Surprisingly, the Ham's test yield positive with 2 of 20 compatible serum. Only other…”
Get more information